(Q46437932)

English

Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Alejandra Hernández-santoyo

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

author name string

Quintana-Hau JD

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Cruz-Olmos E

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

López-Sánchez MI

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Sánchez-Castellanos V

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Baiza-Durán L

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

González JR

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Tornero-Montaño

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Mondragón-Flores R

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Drug Development and Industrial Pharmacy

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

31

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

263-269

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea.

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Cyclo-oxygenase inhibitors in ophthalmology

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Ocular preparations: the formulation approach

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Cyclosporine A delivery to the eye: A pharmaceutical challenge

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Temperature and pH-dependent supramolecular self-assembly of amelogenin molecules: a dynamic light-scattering analysis

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Biopharmaceutical considerations in topical ocular drug delivery

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Topical nonsteroidal anti-inflammatory therapy in ophthalmology

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Distribution of cyclosporin A in the cornea after topical or oral administration

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1081%2FDDC-52058

21 January 2018

Identifiers

10.1081/DDC-52058

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15830722

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46437932&oldid=2111710053"